Kohler P - Search Results

1

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.

Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Bailey H, et al. Among authors: kohler p. Invest New Drugs. 1992 Nov;10(4):279-87. doi: 10.1007/BF00944182. Invest New Drugs. 1992. PMID: 1487401 Clinical Trial.

2

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.

Berlin J, King AC, Tutsch K, Findlay JW, Kohler P, Collier M, Clendeninn NJ, Wilding G. Berlin J, et al. Among authors: kohler p. Invest New Drugs. 1994;12(2):137-41. doi: 10.1007/BF00874444. Invest New Drugs. 1994. PMID: 7860231 Clinical Trial.

3

Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.

Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Hong R, Sondel PM. Kohler PC, et al. Cancer Invest. 1989;7(3):213-23. doi: 10.3109/07357908909039840. Cancer Invest. 1989. PMID: 2790538 Clinical Trial.

4

Phase 1 clinical evaluation of recombinant interleukin-2.

Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Sondel PM. Kohler PC, et al. Prog Clin Biol Res. 1987;244:161-72. Prog Clin Biol Res. 1987. PMID: 3498945

5

Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.

Kohler PC, Hamm JT, Wiebe VJ, DeGregorio MW, Shemano I, Tormey DC. Kohler PC, et al. Breast Cancer Res Treat. 1990 Aug;16 Suppl:S19-26. doi: 10.1007/BF01807140. Breast Cancer Res Treat. 1990. PMID: 2149280 Clinical Trial.

6

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.

Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. Among authors: kohler pc. J Natl Cancer Inst. 1988 Nov 16;80(18):1451-61. doi: 10.1093/jnci/80.18.1451. J Natl Cancer Inst. 1988. PMID: 3263508 Clinical Trial.

7

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. Among authors: kohler pc. J Natl Cancer Inst. 1988 Mar 2;80(1):60-3. doi: 10.1093/jnci/80.1.60. J Natl Cancer Inst. 1988. PMID: 3257526

8

The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.

Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Bechhofer R, Storer B, Sondel PM. Albertini MR, et al. Among authors: kohler pc. Cancer. 1990 Dec 15;66(12):2457-64. doi: 10.1002/1097-0142(19901215)66:12<2457::aid-cncr2820661203>3.0.co;2-l. Cancer. 1990. PMID: 2249185 Clinical Trial.

9

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. Sosman JA, et al. Among authors: kohler pc. Cancer Invest. 1991;9(1):35-48. doi: 10.3109/07357909109032798. Cancer Invest. 1991. PMID: 2012995 Review.

10

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Sondel PM, et al. Among authors: kohler pc. Cancer Res. 1988 May 1;48(9):2561-7. Cancer Res. 1988. PMID: 3258545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

727 results

Search Page

Filters